Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Sunday, April 11, 1999 Published at 19:59 GMT 20:59 UK


Health

Salmonella treatment for cancer

A genetically engineered form of salmonella may be beneficial for humans

A genetically-engineered form of salmonella could be effective in treating cancer, claims its manufacturer.

Salmonella is traditionally associated with food poisoning, but scientists say a genetically-engineered form of the bug could be beneficial for humans.

Vion Pharmaceuticals has applied for a licence to test its treatment, known as the TAPET vector, on humans in both the US and Europe.

It says tests on monkeys and mice have shown the treatment is effective and safe.

Scientists from the company presented their findings to the American Association for Cancer Research on Sunday.

They claim the vectors can help improve the targeting of anti-cancer drugs at tumours.

Even without anti-cancer drugs attached to them, they can inhibit the growth of primary and spreading tumours by more than 90% and prolong the lives of mice which have been implanted with human cancer tissue, claims Vion.

Toxicity reduction

David Bermudes, associate director of biology at Vion, says genetically engineering salmonella means its toxic effects, such as septic shock, are reduced by as much as 10,000 times.

Vion claims cynomolgous monkeys given the genetically-engineered bacteria in high doses showed no toxic effects.

It says the treatment is also rapidly cleared from the bloodstream and is undetectable within 24 hours.

When it was injected intravenously into mice which had been transplanted with human melanoma, colon, lung, prostate and breast tumours, it effectively targeted tumours rather than other tissue.

It accumulated in tumour tissue up to 500 times more than in non-cancerous tissue.

Mice given the vector treatment lived longer than those not given it.

Dr Ivan King, vice president of biology at Vion, said: "These new findings further support Vion's position that TAPET organisms should be safe for use in humans and offer considerable potential as a new approach to the treatment of cancer."



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


Health Contents

Background Briefings
Medical notes

Relevant Stories

14 Feb 99 | Health
Breast cancer fears torment women

05 Feb 99 | Health
Best cancer treatment 'a human right'

28 Jan 99 | Health
Brain cancer pill breakthrough

05 Jan 99 | Health
Hopes for gentler cancer treatment

05 Jan 99 | Health
Dental risk for cancer children

05 Jan 99 | Health
Hopes for gentler cancer treatment





Internet Links


American Association for Cancer Research

Vion Pharmaceuticals

Cancer Research Campaign


The BBC is not responsible for the content of external internet sites.




In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99